MX2022014369A - Métodos de tratamiento de la hipertrofia del ventrículo izquierdo. - Google Patents
Métodos de tratamiento de la hipertrofia del ventrículo izquierdo.Info
- Publication number
- MX2022014369A MX2022014369A MX2022014369A MX2022014369A MX2022014369A MX 2022014369 A MX2022014369 A MX 2022014369A MX 2022014369 A MX2022014369 A MX 2022014369A MX 2022014369 A MX2022014369 A MX 2022014369A MX 2022014369 A MX2022014369 A MX 2022014369A
- Authority
- MX
- Mexico
- Prior art keywords
- methods
- left ventricle
- subject
- ventricle hypertrophy
- disclosed
- Prior art date
Links
- 238000000034 method Methods 0.000 title abstract 11
- 206010020880 Hypertrophy Diseases 0.000 title abstract 7
- 210000005240 left ventricle Anatomy 0.000 title abstract 7
- 210000004027 cell Anatomy 0.000 abstract 4
- 230000000747 cardiac effect Effects 0.000 abstract 2
- ANIAZGVDEUQPRI-ZJQCGQFWSA-N etelcalcetide Chemical compound NC(N)=NCCC[C@H](C(N)=O)NC(=O)[C@@H](C)NC(=O)[C@@H](CCCN=C(N)N)NC(=O)[C@@H](CCCN=C(N)N)NC(=O)[C@@H](CCCN=C(N)N)NC(=O)[C@@H](C)NC(=O)[C@@H](CSSC[C@H](N)C(O)=O)NC(C)=O ANIAZGVDEUQPRI-ZJQCGQFWSA-N 0.000 abstract 2
- 229950006502 etelcalcetide Drugs 0.000 abstract 2
- 108091022127 etelcalcetide hydrochloride Proteins 0.000 abstract 2
- 230000004217 heart function Effects 0.000 abstract 2
- 210000002865 immune cell Anatomy 0.000 abstract 2
- 238000007634 remodeling Methods 0.000 abstract 2
- 108010019670 Chimeric Antigen Receptors Proteins 0.000 abstract 1
- 206010028980 Neoplasm Diseases 0.000 abstract 1
- 108091008874 T cell receptors Proteins 0.000 abstract 1
- 102000016266 T-Cell Antigen Receptors Human genes 0.000 abstract 1
- 239000000427 antigen Substances 0.000 abstract 1
- 102000036639 antigens Human genes 0.000 abstract 1
- 108091007433 antigens Proteins 0.000 abstract 1
- 201000011510 cancer Diseases 0.000 abstract 1
- 238000001727 in vivo Methods 0.000 abstract 1
- 230000002688 persistence Effects 0.000 abstract 1
- 238000002560 therapeutic procedure Methods 0.000 abstract 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- A61K38/22—Hormones
- A61K38/29—Parathyroid hormone (parathormone); Parathyroid hormone-related peptides
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
- A61K38/08—Peptides having 5 to 11 amino acids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P5/00—Drugs for disorders of the endocrine system
- A61P5/18—Drugs for disorders of the endocrine system of the parathyroid hormones
- A61P5/20—Drugs for disorders of the endocrine system of the parathyroid hormones for decreasing, blocking or antagonising the activity of PTH
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/04—Inotropic agents, i.e. stimulants of cardiac contraction; Drugs for heart failure
Abstract
Se describen métodos para el tratamiento de un sujeto con hipertrofia del ventrículo izquierdo. También se describen métodos para ralentizar o retrasar la progresión de la hipertrofia del ventrículo izquierdo, así como métodos para mediar en la remodelación cardíaca y para mejorar la función cardíaca en sujetos con hipertrofia del ventrículo izquierdo. Los métodos comprenden la administración de etelcalcetida por vía parenteral a un sujeto.
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US202063025626P | 2020-05-15 | 2020-05-15 | |
| PCT/US2021/032597 WO2021231960A1 (en) | 2020-05-15 | 2021-05-14 | Methods of treating left ventricle hypertrophy |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| MX2022014369A true MX2022014369A (es) | 2023-02-23 |
Family
ID=76502804
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| MX2022014369A MX2022014369A (es) | 2020-05-15 | 2021-05-14 | Métodos de tratamiento de la hipertrofia del ventrículo izquierdo. |
Country Status (7)
| Country | Link |
|---|---|
| US (1) | US20230201313A1 (es) |
| EP (1) | EP4149507A1 (es) |
| JP (1) | JP2023525884A (es) |
| AU (1) | AU2021270318A1 (es) |
| CA (1) | CA3178367A1 (es) |
| MX (1) | MX2022014369A (es) |
| WO (1) | WO2021231960A1 (es) |
Family Cites Families (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| HUE034209T2 (en) | 2013-06-28 | 2018-02-28 | Amgen Inc | AMG 416 stable liquid preparation (velcalcetide) |
-
2021
- 2021-05-14 AU AU2021270318A patent/AU2021270318A1/en active Pending
- 2021-05-14 MX MX2022014369A patent/MX2022014369A/es unknown
- 2021-05-14 CA CA3178367A patent/CA3178367A1/en active Pending
- 2021-05-14 WO PCT/US2021/032597 patent/WO2021231960A1/en active Application Filing
- 2021-05-14 JP JP2022569583A patent/JP2023525884A/ja active Pending
- 2021-05-14 US US17/925,581 patent/US20230201313A1/en active Pending
- 2021-05-14 EP EP21733256.8A patent/EP4149507A1/en active Pending
Also Published As
| Publication number | Publication date |
|---|---|
| US20230201313A1 (en) | 2023-06-29 |
| JP2023525884A (ja) | 2023-06-19 |
| EP4149507A1 (en) | 2023-03-22 |
| AU2021270318A1 (en) | 2022-12-15 |
| CA3178367A1 (en) | 2021-11-18 |
| WO2021231960A1 (en) | 2021-11-18 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| AR112328A1 (es) | Composiciones y métodos para tratamiento de cáncer usando bifidobacterium animalis ssp. lactis | |
| WO2019094642A8 (en) | T cell manufacturing compositions and methods | |
| EA201201186A1 (ru) | ИСПОЛЬЗОВАНИЕ ErbB3 ИНГИБИТОРОВ В ЛЕЧЕНИИ ТРИЖДЫ НЕГАТИВНОГО И БАЗАЛЬНО-ПОДОБНОГО ВИДОВ РАКА МОЛОЧНОЙ ЖЕЛЕЗЫ | |
| MX2020010913A (es) | Anticuerpos anti-cd27 y anti-pd-l1 y constructos biespecíficos. | |
| MD3883606T2 (ro) | Metodă sigură și eficientă de tratament al colitei ulcerative cu anticorpi anti-IL12/IL23 | |
| BR112016007100A2 (pt) | tratamento contra tumor combinado usando interferon gama e minicélulas carregadas com fármaco dirigidas a ligantes biespecíficos | |
| WO2020000035A8 (en) | Modified t cells and uses thereof | |
| EP4253422A3 (en) | Antibodies that bind tumor tissue, and their diagnostic and therapeutic uses | |
| CO2022009086A2 (es) | Tratamiento que involucra células efectoras inmunitarias modificadas genéticamente para expresar receptores de antígenos | |
| MX2022014369A (es) | Métodos de tratamiento de la hipertrofia del ventrículo izquierdo. | |
| PH12021551235A1 (en) | Elacestrant in combination with abemaciclib in women with breast cancer | |
| CL2023000437A1 (es) | Metodos y composiciones de fabricacion de celulas t | |
| Dholaria et al. | Autologous stem cell transplantation in central nervous system lymphoma: A multicenter retrospective series and a review of the literature | |
| MX2021013222A (es) | Metodos para tratar el cancer con un anticuerpo anti-pd-l1. | |
| RU2548506C1 (ru) | Способ восстановительного лечения онкогинекологических больных репродуктивного возраста раком тела и шейки матки после проведенного противоопухолевого лечения | |
| Gulaga et al. | THE INFLUENCE OF EPLERENON ON THE INTRACARDIAC HEMODYNAMICS IN PATIENTS WITH MYOCARDIAL INFARCTION | |
| 梁远红 et al. | Clinical efficacy and predictor of cardiac resynchronization therapy on left bundle branch block-associated heart dysfunction | |
| EA201591737A1 (ru) | Доставка sdf-1 для лечения ишемизированной ткани | |
| Wollmann | Effects of different right ventricular pacing sites on QRS duration in patients receiving permanent dual chamber pacemakers | |
| Zegard et al. | P411 Heart failure after transcatheter and surgical aortic valve replacement: impact of pacemaker implantation | |
| Certelli et al. | Gynaecology & Obstetrics | |
| MX2023004899A (es) | Direccionamiento de src-3 en celulas inmunitarias como un inmunomodulador terapeutico para el tratamiento de cancer. | |
| Khaled et al. | A novel cardiac extracorporeal shock wave for enhancing the efficacy of cell therapy | |
| Teryushkova et al. | TREATMENT OF RADIATION-INDUCED COLOVAGINAL FISTULA WITH AUTOLOGOUS FAT GRAFTING | |
| AU2022362079A1 (en) | T cell manufacturing compositions and methods |